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Abstract
Background: Severe combined immunodeficiency is within a heterogeneous group of inherited defects
throughout the development of T- and/or B-lymphocytes. Mutations in recombinase-activating genes 1 or 2
(RAG1/2) represent approximately 10% of all SCID cases. RAG1/2 are essential for V(D)J rearrangement of the B- and
T-cell receptors.
Objectives: The aim of this study was to review clinical, immunological and molecular findings of Turkish SCID
patients with RAG1 defects and to draw attention to novel mutations, genotype-phenotype correlations and the
high rate of BCG infections within this group.
Methods: Eleven patients (F/M: 6/5) were included. Molecular, immunological and clinical data were evaluated.
Results: Five patients were classified as T-B-NK + SCID, four patients as T + B-NK + SCID (two of these patients
were diagnosed as classical Omenn syndrome) and two patients as T + B + NK + SCID with respect to clinical
presentations and immunological data. Mean age of the whole study group, mean age at onset of symptoms and
mean age at diagnosis were: 33.0 ± 42.8, 3.1 ± 3.3 and 10.4 ± 13.5 months, respectively. Consanguinity rate was
54%. Some novel mutations were found in RAG1 gene in addition to previously reported mutations. Genotype-
phenotype correlation was not significantly apparent in most of the cases. BCG infection was observed in 36.4% of
patients (two BCG-osis and two BCG-itis).
Conclusion: Epigenetic factors such as compound genetic defects, enviromental factors, and exposure to recurrent
infections may modify phenotypical characteristics of RAG deficiencies. Inoculation of live vaccines such as BCG
should be postponed until primary immunodeficiency disease is excluded with appropriate screening tests in
suspected cases.
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Background
Severe combined immunodeficiency (SCID) syndromes
embrace common phenotypic presentation of a range of
genetic disorders [1]. According to recent immunologi-
cal and genetic findings, SCID can be subdivided into
11 conditions. These conditions are abnormally
increased apoptosis of the lymphocytes (reticular dys-
genesis caused by adenylate kinase 2 (AK2), adenosine-
deaminase-deficiency), defects of cytokine signaling (X-
linked SCID, IL7-receptor-a, JAK3- deficiency), defects
in T-cell-receptor (TCR) assembly and signaling (RAG1/
2, DNAPKcs, Artemis and Cernunnos, CD3 defects) and
general T-cell signaling defects associated with calcium
release-activated Ca++ channels (CRAC) and yet unclas-
sified defects such as the deficiency of RNA component
of mitochondrial RNA processing endoribonuclease
(RMPR) also known as Cartilage-Hair-Hypoplasia [2-4].
Mutations in recombinase activating genes 1 or 2
(RAG1/2) represent approximately 10% of all SCID
cases [5]. These genes are located within human11p13
chromosome. Their products; RAG1 and RAG2 proteins
are essential for V(D)J rearrangement of the B (BCR)
and TCR during T and B cell development [6-8].
The first mutation in the RAG1 gene was identified
in 1996 by Schwarz et al [9]. Complete RAG defi-
ciency (RAGD) with no V(D)J (< 1% recombination
activity of wild type) is associated with classical SCID
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and absence of T and B cells. It is estimated that
RAG1/2 is involved in approximately 50% of all
patients with T-B-NK + SCID phenotype [10]. In
RAGD with residual V(D)J activity (> 1% recombina-
tion activity of wild type), several clinical and immu-
nological subtypes have been described; such as
RAGD with skin inflammation and ab T-cell expan-
sion (classical Omenn syndrome), RAGD with skin
inflammation and without T-cell expansion (incom-
plete Omenn syndrome), RAGD with gδ T-cell expan-
sion and RAGD with granulomas [2,3,11]. B cell levels
and immunoglobulin concentrations are almost nor-
mal or only slightly reduced in patients with hypo-
morphic mutations [12]. In recent studies,
autoimmune cytopenia and resistant CMV infection
are reported in hypomorphic RAG mutated patients
[12-14]. These patients usually present with severe
and life-threatening bacterial, viral and fungal infec-
tions in early infancy regardless of SCID type and the
underlying genetic defect. Some patients with RAG
deficiency may present later in life as combined
immunodeficiency with granuloma formation [15].
Patients with SCID also experience opportunistic
infections of mycobacterium species and complications
after vaccination with Bacille Calmette-Guerin (BCG).
The aim of this study was to review clinical, immuno-
logical and molecular findings of Turkish SCID patients
with RAG1 defects admitted to a Pediatric Immunology
Department in the western region of the country and to
draw attention to novel mutations, genotype-phenotype
correlations and high frequency of BCG infections.
Patients and methods
Patients
Eleven patients with the diagnosis of SCID in respect to
severe upper and lower respiratory tract infections from
2002 to 2010 in Ege University Faculty of Medicine,
Department of Pediatric Immunology, Izmir, Turkey;
were reviewed in this study. An evaluation sheet was
used to summarize demographic information of patients
including name, gender, date of birth, age of onset of
symptoms, clinical symptoms, age at diagnosis, family
history and consanguinity, previous history of medica-
tions and vaccination, and laboratory and molecular
data. The patients were diagnosed and classified accord-
ing to clinical and laboratory criteria of SCID reported
by IUIS Expert Committee on Primary Immunodeficien-
cies [16].
All patients were screened for mutations in RAG1,
RAG2 gene. Ten age-matched, healthy people (mean
age: 27.4 ± 2.1 years) served as controls for the analyses
of genetic data. This study was approved by the Ethics
Commitee at Ege University, and an informed consent
was obtained for each participating patient.
Cellular and immunological assays
Complete blood count with peripheral blood smear eva-
luation, serum immunoglobulins by nephelometry (Dade
Behring BNII Nephelometer Analyzer, Germany), anti-
body response to previous vaccines, and lymphocyte
phenotyping (T, B, and NK cells) by flow cytometry
(FACSCalibur, Becton-Dickinson, USA) were the stan-
dard laboratory investigations performed for our
patients.
Clinical samples and DNA isolation
Peripheral blood samples were obtained from the
patients by venipuncture. Genomic DNA was then
extracted from the blood samples using standard techni-
ques [17].
Mutations analyses at the RAG-1 and RAG-2 loci
Because of the restricted expression of RAG-1 and RAG-
2 genes and the fact that the coding region of each gene
is contained in a single exon, coding sequences were
amplified from genomic DNA. Primers were designed
for the amplification of the RAG genes based on the
sequences reported in databases (RAG-1, M29474; RAG-
2, M94633). RAG gene sequence information was
obtained as previously specified [18]. Alternatively, the
RAG-1 gene was amplified in 2 segments (94-1852 and
1781-3262), and the RAG-2 gene was amplified in one
segment (1201-2922) with the following primers: RAG-
1-90 F, CTG AGC AAG GTA CCT CAG C; RAG-1-
1852R, GCC TTC CAA GAT GTC TTCTTC; RAG-1-
1781 F, GCAAAG AGG TTC CGC TAT GA; RAG-1-
3262R, CAT AAG TGG TTG CCC TAC TT; RAG-2-
1201 F, ATG TCT CTG CAG ATG GTA AC; RAG-2-
2922R, CTG GCC CTT AAT TCA TGT AAC. Sequen-
cing was performed directly on the PCR products puri-
fied from the gel with the Thermosequenase kit
(Amersham Pharmacia Biotech UK, Buckinghamshire,
United Kingdom). For patients who were compound
heterozygotes, mutations were confirmed either by
restriction analysis or by analysis of several clones from
PCR amplification products cloned in TA vector (Invi-
trogen) and sequenced by the dideoxynucleotide chain
termination method using the Sequenase kit (USB), as
previously described [18].
SPSS was used for statistical analyses (Windows Ver-
sion 15.0, SPSS Inc., Chicago, IL).
Results
Eleven patients (F/M: 6/5) with SCID or Omenn Syn-
drome who had RAG mutations were analyzed. Their
demographic findings are listed in Table 1. Among
them, two have been previously reported [14]. Five
patients were classified as T-B-NK + SCID, four patients
as T + B-NK + SCID (two of these patients were
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diagnosed as classical Omenn syndrome) and two
patients as T + B + NK + SCID with respect to clinical
presentations (Table 1) and immunological data (Table
2). Mean age of the whole study group, mean age at
onset of symptoms and mean age at diagnosis were;
33.0 ± 42.8, 3.1 ± 3.3 and 10.4 ± 13.5 months, respec-
tively. Consanguinity was present in 6 (54%) of 11
patients and all of them were second degree relatives.
Positive family history for immunodeficiency was deter-
mined in five patients (45%).
Absolute lymphocyte counts and lymphocyte subset
distributions in the RAGD patients are shown in Table
2. Lymphopenia was documented in 36% of all patients
(in 80% of T-B-NK + SCID patients, and 25% of T +
B-NK + SCID patients). A high variability in the total
lymphocyte count was documented in these groups.
Data on the expression of activation markers (HLA-
DR) was obtained for the subgroups of RAGD SCID
patients. In particular, the T + B-NK + group showed
increased percentages of HLA-DR + cells (100%). Two
groups (T + B- and T-B+) of patients with RAG1
defects had very low proportions of CD19 cells. The
highest NK cell percentages were found in patients
with T-B- SCID (73.2%). Eosinophilia, a well-known
feature of Omenn Syndrome, was observed in 2/4 of
the T + B-patients group, in 1/5 of T-B- patients and
1/2 of T + B + patients. None of the patients have
been shown to produce specific antibodies against vac-
cines, such as tetanus toxoid, Haemophilus Influenza
type B or hepatitis B.
Genotype-phenotype correlation
We investigated the mutations in RAG1 and RAG 2
genes in SCID patients and the control group (Table 2)
and compared them with the clinical phenotypes. The
following findings were detected in 11 SCID patients:
Two novel mutations in four patients
Homozygous mutation of p.R394Q/p.R394Q was found
in three patients of the T-B- group (patient 1- 2-5).
Two of these patients and their parents (no. 1 and 5)
were cousins. Lymphopenia, hypogammaglobulinemia,
early onset of disease symptoms were significant in
these three patients.
Another mutation which was not reported before, in
T-B- SCID group, was p.R776Q, 3047- 3049 del GCC
(patient 3). This female patient had chronic diarrhea
beginning from the neonatal period. The other clinical
findings were hepatomegaly, splenomegaly, dermatitis,
anal fissure and failure to thrive. Direct Coombs test
was positive. In addition to chronic pulmonary infection,
lymphadenopathy was observed both in computerized
tomography of the thorax and the axillary area. Myco-
bacterium bovinum was detected in her sputum and she
began to receive antimycobacterial therapy after the
diagnosis of BCG infection.
Two previously reported mutations in two patients
Homozygous mutation of Q248X in our Omenn Syn-
drome patient (case no.9) has been reported before in
T-B-NK + SCID and Omenn Syndrome cases. Similar
to the previously reported cases, P85fs32X (del A256/
A257) mutation was found in one (case no.11) of our
leaky SCID patients. This case had refractory CMV
infection, autoimmunity and elevated gamma-delta T
cells.
Amino acid changes: Mutations or polymorphisms? (Five
patients)
p.H249R amino acid change (homozygous) was detected
in a T-B-NK + patient (no.4), who was admitted on 40/
365 day because of pulmonary infection and moniliasis
and underwent BMT when he was three months old.
p.H249R amino acid change (heterozygous) was
observed in two of our cases (patients 8 and 10), one
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Table 2 Immunological and genetic findings of patients with RAG1 defects
T-B-NK+ (n = 5) T + B-NK+ (n = 4) T + B + NK+ (n = 2)
Other phenotype n(2) Omenn n(2)
Patient 1 Patient 2 Patient
3




371 546 546 517 312 1372 1840 1080 662 159 1590
IgA (mg/
dl)
< 6 < 6 < 6 < 6 < 6 22 219 49 < 6 8 52
IgM (mg/
dl)
< 17 < 17 < 17 < 17 < 17 222 120 179 < 17 52 75
WBC 7800 8220 532 8280 6780 5900 8740 24700 19200 15500 11000
Abs.lymp
h./mm3
1028 657 180 3120 650 3835 1748 9386 6144 7630 5500
CD3+ % 10 0 0 0 0 56 78 92 78 59 51
CD3 + CD
4+ %
0 0 0 0 0 11 17 19 33 37 9
CD3 + CD
8+ %
10 0 0 0 0 50 55 60 47 19 39




75 43 90 78 63 43 12 2 11 7 16
HLA DR +
T cell %















































The most common symptoms were pneumonia (n = 10), chronic diarrhea (n = 6), infections plus dermatitis (n = 3), infections plus moniliasis (n = 3) or all of these (n = 3). The respiratory tract diseases were the
most frequent infection type. Lymphadenopathy and hepatosplenomegaly were observed in 36% and 90% of RAGD patients, respectively. Auotoimmunity was recorded in three patients. CMV infection was detected















with Omenn Syndrome and one with T + B + SCID.
The Omenn Syndrome case had all the classical clinical
and laboratory findings. He had early-onset generalized
erythroderma, failure to thrive, protracted diarrhea,
hepatosplenomegaly, lymphadenopathy, and eosinophi-
lia. This case had developed left axillary lymphadenopa-
thy six weeks after BCG infection. Mycobacterium
bovinum was isolated from the lymph node (BCGitis).
The other case with T + B + SCID had recurrent pul-
monary infections, splenomegaly and CMV infection.
She received the BCG vaccine before the diagnosis of
SCID and developed bilateral axillary lymphadenopathy
three months after vaccination. Granulomatous lympha-
denitis was observed in lymph node biopsy and Myco-
bacterium bovinum was isolated (BCGitis). Analysis of
the parents of these two patients revealed that the
mothers also had the same findings.
p.H249R/p.K820R amino acid changes (compound het-
erozygous) were observed in two patients of T + B-
group. The male case (patient 7) had diarrhea, recurrent
bronchiolitis and autoantibodies. Several nodules were
observed on his shoulder and gluteal area when he was
three years old. Mycobacterium Bovinum was isolated
both from biopsy of nodules and from bronchoalveolar
lavage fluid (BCGosis). The female case (patient 6) had
recurrent pulmonary infections, diarrhea, hepatomegaly,
splenomegaly, and bronchiectasis,. She is now 13 years
old and receiving regular intravenous immunoglobulin
therapy.
Mutations or amino acid changes have not been
observed in the healthy control group. There was no
mutation in RAG 2 gene in either the patients’ or con-
trol groups.
RAG1base and RAG2base mutation databases
All reported RAG-1 mutations were recorded into data-
bases called RAG1base and RAG2base. These databases
were constructed according to http://www.uta.fi/imt/
bioinfo/RAG1base and/RAG2base.
Mortality and survival
Five patients underwent bone marrow (BMT) or
umblical cord stem cell transplantation. These patients
received bone marrow from sibling (n = 1), haploiden-
tical mother (n = 2) (Patient 11 had 2 BMTs), haploi-
dentical father (n = 1) and matched unrelated (n = 2)
donors. Mean follow-up duration after transplantation
was 9.0 ± 8.9 months. Two patients deceased after
transplantation and 4 patients deceased before trans-
plantation during follow-up. Engraftment was not
achieved in two cases. One of them was a T + B + NK
+ leaky SCID male patient and the donor was his
mother, and the other patient was a T-B-NK + patient
and the donor was his brother. One patient (T + B +
NK + leaky SCID female patient) has fully recovered
after BMT. Two patients are currently being followed
by prophylactic IVIG replacements and they are wait-
ing for the results of matched unrelated donor
screening.
Dıscussıon
Mutations in RAG1 or RAG2 represent approximately
10% of all SCID cases and most of them are T-B-NK +
SCID [16]. For our patients, the frequencies of T-B-NK
+, T + B-NK + and T + B + NK + SCID phenotype
were 45%, 36% and 18%, respectively. All of our patients
fullfilled previously defined clinical criteria for SCID.
Consanguinity (54%) and family history for immunodefi-
ciency (45%) were very high within our patient group. A
high rate of consanguineous marriages (21%) is a social
and health problem in Turkey as a result of some tradi-
tional concepts, especially in eastern regions. Female/
male ratio was found to be 1.2. Because of these findings
and the effect of high consanquinity rate, RAGD is pre-
viously reported to be inherited in an autosomal reces-
sive pattern [18-20].
To date, at least 55 different hypomorphic RAG muta-
tions have been described; however, clear correlation
between the type of mutations and clinical presentations
has not been observed. This may be due to specific
mutations or other genetic factors, or epigenetic
mechanisms. The mutations identified, both in RAG1
and RAG2 genes; can either be severe, leading to null
alleles, or mild, leading to hypomorphic alleles that can
still maintain a residual enzymatic activity of RAG1/2
proteins. Null mutants typically predominate in classical
T-B-SCID, with no productive rearrangement of the T
cell receptor (TCR) or B-cell receptor (BCR); while mis-
sense mutations predominate in Omenn syndrome and
leaky SCID [21,22]. The same mutations in different
individuals usually lead to similar phenotypes. There are
also a few cases in which the same mutation gives rise
to a different clinical presentation. This suggests that yet
unknown factors may play a role in determining the
clinical picture and outcome [21-25].
The hypomorphic mutation, P85fs32X (del A256/
A257) (old nomenclature is k242fsX246 del A368/A369),
demonstrated in our eleventh patient, was previously
reported by Villa A et al [13]. In another report by de
Villartay et al, four unrelated patients, with the same
hypomorphic RAG1 mutations were presented [26]. The
immunological phenotype of Villartay et al’s patients
consisted of a restricted T cell repertoire, with TCR〈b
lymphopenia, but markedly high levels of TCRg™ T
cells. Severe, disseminated CMV infection and autoim-
mune blood cell manifestations shaped their clinical
phenotype. Our patient with the same hypomorphic
mutation had almost the same clinical and laboratory
Kutukculer et al. Italian Journal of Pediatrics 2012, 38:8
http://www.ijponline.net/content/38/1/8
Page 5 of 7
findings, showing a clear correlation between genotype
and phenotype as these 4 patients.
Sobacchi et al [2] have reported 24 RAGD cases and
16 novel mutations in 2006. One of the mutations in
this report was a p.Q248X homozygous mutation
observed in a T-B-SCID case. Our patient (no.9) with
the same mutation had the characteristic findings of
Omenn Syndrome. Asai et al have recently reported
(2011) 4 missense and 1 nonsense mutations in RAG1
of three SCID children [27]. An atypical SCID case with
maternal T cell engrafment carried a homozygous novel
E770K mutation [27]. One case with atypical Omenn
syndrome was compound heterozygous bearing novel
R142X and R396H mutations [27]. The last case with gδ
T- CMV infection was a compound heterozygote bear-
ing novel R474C and L732F mutations in RAG1 [27].
None of our cases was carrying these mutations.
Pico-Knijnenburg et al [28] have reported a family
with three siblings who were identified by early onset
of infections, pneumonia, sepsis, generalized dermatitis,
malnutrition and diarrhea. There was a strong reduc-
tion of T and B cells and a complete block in precur-
sor B cell differentiation in bone marrow that showed
a V(D)J recombination defect [28]. In all siblings, a
heterozygous mutation in RAG1 was identified
(c2571A > G; p.Cys328Tyr) [28]. They thought that, in
case of heterozygous mutations of RAG1 gene, there
might be another defect on the second allele, which
was not picked up with routine methods such as PCR
and sequencing of the coding region. In her cohort of
patients, Villa A also has observed Omenn cases carry-
ing mutations on only one allele and no mutations in
the promoter regions or in other genes involved in
VDJ recombination (personal communication). Accord-
ing to her, a careful single nucleotide polymorphisms
(SNPs) analysis would also be useful to clarify these
patients’ defects.
H249R (one homozygous and two heterozygous
patients in our study) and K820R (two compound het-
erozygous patients) variants have been observed in our
patient group, but not in our small healthy control
group. Notarangelo LD (Boston Children’s Hospital,
USA) has found several normal subjects with these var-
iants and he thought that they could not be disease-
causing-polymorphisms, (personal communication). Our
five patients presented with classical signs, symptoms
and laboratory findings of SCID and our control group
for the molecular analyses included ten people only.
Thus, we suggest that a future study disclosing the func-
tional activity of human RAG mutants would tell us if
these variants are disease causing or polymorphisms. In
addition, analyses of RAG1 gene in at least one-hundred
healthy Turkish people will lead us to know more about
the disease activity of these variations.
High frequency of BCG infection in our study also
needs to be discussed. Yeganeh et al reported that com-
plicated Bacillus Calmette-Guérin (BCG) vaccination
was documented in 18 of 40 SCID cases (45%) following
the routine vaccination at birth [29]. In another study,
incidence of severe adverse reactions after BCG vaccina-
tion was reported as 0.0182 cases per 100,000 vaccina-
tions in Japanese children. Among 39 cases with adverse
reactions, 13 had been diagnosed to have some types of
primary immunodeficiency. Four of them had SCID
[30]. Sadeghi-Shanbestari M et al [31] have reported
that seven of their eleven disseminated BCG infection
and primary immunodeficiency patients were SCID
cases. From these seven SCID and BCG infection cases,
four patients had T-B-NK + SCID; probably RAG genes
were involved [31]. The same authors have also reported
a novel RAG2 mutation in a patient with SCID and
BCG disease [32]. Four of our 11 RAGD cases (36.4%)
had BCG disease (2 BCG-itis and 2 BCG-osis) and had
to receive anti-mycobacterial therapy. The clinical find-
ings and management of the patients who had docu-
mented BCG infection were worse than the rest of our
group.
We reach to several conclusions from this review of
our RAGD patients:
Epigenetic factors such as compound genetic defects,
enviromental factors and exposure to infectious agents
may modify phenotypical characteristics of RAGD.
Homozygous mutation of p.R394Q/p.R394Q and p.
R776Q, 3047-3049 del GCC mutations are novel and
they are causing serious T-B-NK + SCID.
It is very important to increase the awareness of
pediatricians for early diagnosis and treatment of these
patients with RAG defects.
Inoculation of live vaccines such as BCG should be
postponed in suspected cases for primary immunodefi-
ciency disease, until appropriate screening tests exclude
this diagnosis. Therefore, knowledge of previous cases
with immunodeficiency within the same family is benefi-
cial for early diagnosis and decision for postponing BCG
in such patients.
Acknowledgements
This work was partly supported by a grant from Dubai Harvard Foundation
Medical Research (DHFMR). We would like to thank to Dr. Luigi D.
Notarangelo and Dr. Raif Geha for their excellent support.
Authors’ contributions
AB carried out the molecular genetic studies. NG and NEK reviewed the data
and wrote the paper. NK and GA analyzed the data and edited the
manuscript. All authors read and approved the final manuscript.
Competing interests
The authors declare that they have no competing interests.
Received: 20 May 2011 Accepted: 16 March 2012
Published: 16 March 2012
Kutukculer et al. Italian Journal of Pediatrics 2012, 38:8
http://www.ijponline.net/content/38/1/8
Page 6 of 7
References
1. Ehl S, Schwarz K, Enders A, Duffner U, Pannicke U, Kühr J, Mascart F,
Schmitt-Graeff A, Niemeyer C, Fisch P: A variant of SCID with specific
immune responses and predominance of ©™ T cells. J Clin Invest 2005,
115:3140-8.
2. Sobacchi C, Marrella V, Rucci F, Vezzoni P, Villa A: RAG-dependent primary
immunodeficiencies. Hum Mutat 2006, 27:1174-84.
3. Niehues T, Perez-Becker R, Schuetz C: More than just SCID–The
phenotypic range of combined immunodeficiencies associated with
mutations in the recombinase activating genes (RAG) 1 and 2. Clin
Immunol 2010, 135:183-92.
4. Pessach I, Walter J, Notarangelo LD: Recent advances in primary
immunodeficiencies: identification of novel genetic defects and
unanticipated phenotypes. Pediatr Res 2009, 65:3R-12R.
5. Fischer A: Have we seen the last variant of severe combined
immunodeficiency? N Engl J Med 2003, 349:1789-92.
6. Schatz DG, Oettinger MA, Baltimore D: The V(D)J recombination activating
gene, RAG-1. Cell 1989, 59:1035-48.
7. Oettinger MA, Schatz DG, Gorka C, Baltimore D: RAG-1 and RAG-2,
adjacent genes that synergistically activate V(D)J recombination. Science
1990, 248:1517-52.
8. Ohm-Laursen L, Nielsen C, Fisker N, Lillevang ST, Barington T: Lack of
Nonfunctional B-cell Receptor Rearrangements in a Patient with Normal
B Cell Numbers Despite Partial RAG1 Deficiency and Atypical SCID/
Omenn Syndrome. J Clin Immunol 2008, 28:588-92.
9. Schwarz K, Gauss GH, Ludwig L, Pannicke U, Li Z, Lindner D, Friedrich W,
Seger RA, Hansen-Hagge TE, Desiderio S, Lieber MR, Bartram CR: RAG
mutations in human B cell-negative SCID. Science 1996, 274:97-9.
10. Buckley RH, Schiff RI, Schiff SE, Markert ML, Williams LW, Harville TO,
Roberts JL, Puck JM: Human severe combined immunodeficiency:
genetic, phenotypic, and functional diversity in one hundred eight
infants. J Pediatr 1997, 130:378-87.
11. Giblin W, Chatterji M, Westfield G, Masud T, Theisen B, Cheng HL, DeVido J,
Alt FW, Ferguson DO, Schatz DG, Sekiguchi J: Leaky severe combined
immunodeficiency and aberrant DNA rearrangements due to a
hypomorphic RAG1 mutation. Blood 2009, 113:2965-75.
12. Pasic S, Djuircic S, Ristic G, Slavkovic B: Recombinase-activating gene 1
immunodeficiency: differant immunological phenotypes in three
siblings. Acta Pediatr 2009, 98:1062-64.
13. Villa A, Santagata S, Bozzi F, Giliani S, Frattini A, Imberti L, Gatta LB,
Ochs HD, Schwarz K, Notarangelo LD, Vezzoni P, Spanopoulou E: Partial V
(D)J recombination leads to Omenn syndrome. Cell 1998, 93:885-96.
14. Karaca NE, Aksu G, Genel F, Gulez N, Can S, Aydinok Y, Aksoylar S, Karaca E,
Altuglu I, Kutukculer N: Diverse phenotypic and genotypic presentation
of RAG1mutations in two cases with SCID. Clin Exp Med 2009, 9:339-42.
15. Schuetz C, Huck K, Gudowius S, Megahed M, Feyen O, Hubner B,
Schneider DT, Manfras B, Pannicke U, Willemze R, Knuchel R, Gobel U,
Schulz A, Borkhardt A, Friedrich W, Schwarz K, Niehues T: An
immunodeficiency disease with RAG mutations and granulomas. N Eng J
Med 2008, 358:2030-8.
16. Notarangelo LD, Fischer A, Geha RS, Casanova JL, Chapel H, Conley ME,
Rundles CC, Etzioni A, Hammartröm L, Nonoyama S, Ochs HD, Puck J,
Roifman C, Seger R, Wedgwood J: Primary immunodeficiencies: 2009
update. J Allergy Clin Immunol 2009, 124:1161-78.
17. Miller SA, Dykes DD, Polesky HF: A simple salting out procedure for
extracting DNA from human nucleated cells. Nucleic Acids Res 1988,
16:1215.
18. Alsmadi O, Al-Ghonaium A, Al-Muhsen S, Arnaout R, Al-Dhekri H, Al-Saud B:
Molecular analysis of T-B-NK + severe combined immunodeficiency and
Omenn syndrome cases in Saudi Arabia. BMJ Med Gen 2009, 10:116.
19. El Mouzan MI, Al Salloum AA, Al Herbish AS, Qurachi MM, Al Omar AA:
Consanguinity and major genetic disorders in Saudi children: a
community-based cross-sectional study. Ann Saudi Med 2008, 28:169-73.
20. Yeganeh M, Heidarzade M, Pourpak Z, Parvaneh N, Rezaei N,
Gharagozlou M, Movahedi M, Shabestari MS, Mamishi S,
Aghamohammadi A, Moin M: Severe combined immunodeficiency: a
cohort of 40 patients. Pediatr Allergy Immunol 2008, 19:303-6.
21. Villa A, Sobacchi C, Notarangelo LD, Bozzi F, Abinun M, Abrahamsen TG,
Arkwright PD, Baniyash M, Brooks EG, Conley ME, Cortes P, Duse M, Fasth A,
Filipovich AM, Infante AJ, Jones A, Mazzolari E, Muller SM, Pasic S,
Rechavi G, Sacco MG, Santagata S, Schroeder ML, Seger R, Strina D,
Ugazio A, Väliaho J, Vihinen M, Vogler LB, Ochs H, Vezzoni P, Friedrich W,
Schwarz K: V(D)J recombination defects in lymphocytes due to RAG
mutations: severe immunodeficiency with a spectrum of clinical
presentations. Blood 2001, 97:81-8.
22. Villa A, Notaragelo LD, Roifman CM: Omenn syndrome: Inflammation in
leaky severe combined immunodeficiency. J Allergy Clın Immunol 2008,
1082-1086.
23. Xiao Z, Yannone SM, Dunn E, Cowan MJ: A novel missense RAG-1
mutation results in T-B-NK + SCID in Athabascan-speaking Dine Indians
from the Canadian NorthwestTerritories. Eur J Hum Genet 2009, 17:205-12.
24. Corneo B, Moshous D, Güngör T, Wulffraat N, Philippet P, Le Deist FL,
Fischer A, de Villartay JP: Identical mutations in RAG1 or RAG2 genes
leading to defectives V(D)J recombinase activity can cause either T-B-
severe combined immunodeficiency or Omenn syndrome. Blood 2001,
97:2772-76.
25. Gruber TA, Shah AJ, Hernandez M, Crooks GM, Abdel-Azim H, Gupta S,
McKnight S, White D, Kapoor N, Kohn DB: Clinical and genetic
heterogeneity in Omenn syndrome and severe combined immune
deficiency. Pediatr Transplantation 2009, 13:244-50.
26. de Villartay JP, Lim A, Al-Mousa H, Dupont S, Déchanet-Merville J, Coumau-
Gatbois E, Gougeon ML, Lemainque A, Eidenschenk C, Jouanguy E, Abel L,
Casanova JL, Fischer A, Le Deist F: A novel immunodeficiency associated
with hypomorphic RAG1 mutations and CMV infection. J Clin Invest 2005,
115:3291-99.
27. Asai E, Wada T, Sakakibara Y, Toga A, Toma T, Shimizu T, Nampoothiri S,
İmai K, Nonoyama S, Morio T, Muramatsu H, Kamachi Y, Ohara O, Yachie A:
Analysis of mutations and recombination activity in RAG-deficient
patients. Clin Immunol 2011, 138:172-7.
28. Pico-Knijnenburg I, Jspeert H, Pac M, Turul T, Hartwig N, Sanders E, Tezcan I,
Bernatowska E, van Dongen J, van der Burg M, Wolska-Kusnierz B: Can
heterozygous RAG1 mutations be disease-causing? XIVth Meeting of the
European Society for Immunodeficiencies (ESID) 2010, 203-4, Istanbul, abstract
book.
29. Yeganeh M, Heidarzade M, Pourpak Z, Parvaneh N, Rezaei N,
Gharagozlou M, Movahedi M, Shabestari MS, Mamishi S,
Aghamohammadi A, Moin M: Severe combined immunodeficiency: a
cohort of 40 patients. Pediatr Allergy Immunol 2008, 19:303-6.
30. Toida I, Nakata S: Severe adverse reactions after vaccination with
Japanese BCG vaccine: a review. Kekkaku 2007, 82:809-24.
31. Sadeghi-Shanbestari M, Ansarin K, Maljaei SH, Rafeey M, Pezeshki Z,
Kousha A, Baradaran R, Casanova JL, Feinberg J, de Villartay JP:
Immunologic aspects of patients with disseminated bacille Calmette-
Guerin disease in North-west of Iran. Ital J Pediatr 2009, 23:35-42.
32. Sadeghi-Shabestari M, Vesal S, Jabbarpour-Bonyadi M, de Villartay JP,
Fischer A, Rezaei N: Novel RAG2 mutation in a patient with T-B- severe
combined immunodeficiency and disseminated BCG disease. J Investig
Allergol Clin Immunol 2009, 19:494-96.
doi:10.1186/1824-7288-38-8
Cite this article as: Kutukculer et al.: Novel mutations and diverse
clinical phenotypes in recombinase-activating gene 1 deficiency. Italian
Journal of Pediatrics 2012 38:8.
Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color figure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
Kutukculer et al. Italian Journal of Pediatrics 2012, 38:8
http://www.ijponline.net/content/38/1/8
Page 7 of 7
